217330 — Cytogen Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapSucker Stock

Annual income statement for Cytogen, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	643	348	761	3,184	10,911
Cost of Revenue
Gross Profit	-130	57.3	195	846	2,829
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	7,230	13,206	12,068	17,171	24,945
Operating Profit	-6,587	-12,858	-11,307	-13,987	-14,035
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-5,010	-13,323	-18,692	-16,179	-17,931
Provision for Income Taxes
Net Income After Taxes	-4,889	-10,871	-18,771	-15,770	-17,116
Minority Interest
Net Income Before Extraordinary Items
Net Income	-4,889	-10,871	-18,771	-15,770	-17,117
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-4,889	-10,871	-18,771	-15,770	-17,117
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-289	-642	-1,070	-781	-661
Dividends per Share